Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Value Health. 2018 Nov;21(11):1286-1290. doi: 10.1016/j.jval.2018.04.1826. Epub 2018 May 18.
Prescription drug shortages can disrupt essential patient care and drive up drug prices.
To evaluate some predictors of shortages within a large cohort of generic drugs in the United States and to determine the association between drug shortages and changes in generic drug prices.
This was a retrospective cohort study. Outpatient prescription claims from commercial health plans between 2008 and 2014 were analyzed. Seven years of data were divided into fourteen 6-month periods; the first period was designated as the baseline period. The first model estimated the probability of experiencing a drug shortage using drug-specific competition levels, market sizes, formulations (e.g., capsules), and drug prices as predictors. The second model estimated the percentage change in drug prices from baseline on the basis of drug shortage duration.
From 1.3 billion prescription claims, a cohort of 1114 generic drugs was identified. Low-priced generic drugs were at a higher risk for drug shortages compared with medium- and high-priced generic drugs, with odds ratios of 0.60 (95% confidence interval [CI] 0.44-0.82) and 0.72 (95% CI 0.52-0.99), respectively. Compared with periods of no shortage, drug shortages lasting less than 6 months, 6 to 12 months, 12 to 18 months, and at least 18 months had corresponding price increases of 6.0% (95% CI 4.7-7.4), 10.9% (95% CI 8.5-13.4), 14.2% (95% CI 10.6-17.9), and 14.0% (95% CI 9.1-19.2), respectively.
Study findings may not be generalizable to drugs that became generic after 2008 or those commonly used in an inpatient setting. The lowest priced drugs are at a substantially elevated risk of experiencing a drug shortage. Periods of drug shortages were associated with modest increases in drug prices.
处方药物短缺会扰乱基本的患者护理并推高药物价格。
评估在美国大量通用药物中短缺的一些预测因素,并确定药物短缺与通用药物价格变化之间的关联。
这是一项回顾性队列研究。分析了 2008 年至 2014 年商业健康计划的门诊处方。七年的数据分为 14 个 6 个月的时间段;第一个时间段被指定为基线期。第一个模型使用药物特定竞争水平、市场规模、制剂(如胶囊)和药物价格作为预测因素,估计药物短缺的可能性。第二个模型根据药物短缺持续时间估计药物价格从基线的百分比变化。
从 13 亿张处方中,确定了 1114 种通用药物的队列。与中高价通用药物相比,低价通用药物发生药物短缺的风险更高,优势比分别为 0.60(95%置信区间[CI] 0.44-0.82)和 0.72(95%CI 0.52-0.99)。与无短缺期相比,持续时间少于 6 个月、6 至 12 个月、12 至 18 个月和至少 18 个月的药物短缺分别对应价格上涨 6.0%(95%CI 4.7-7.4)、10.9%(95%CI 8.5-13.4)、14.2%(95%CI 10.6-17.9)和 14.0%(95%CI 9.1-19.2)。
研究结果可能不适用于 2008 年后成为通用药物或常用于住院患者的药物。价格最低的药物发生药物短缺的风险大大增加。药物短缺期与药物价格适度上涨相关。